# decryptor user guide (v 1.1.3)

## Miroslav Hruska

December 29, 2017

## Contents

| 1 | Intr | oduction              | 2  |
|---|------|-----------------------|----|
|   | 1.1  | Applications          | 2  |
|   | 1.2  |                       | 2  |
| 2 | Brov | vsing results         | 3  |
|   | 2.1  | Login                 | 3  |
|   |      | 2.1.1 Root page       | 3  |
|   |      | 2.1.2 Login page      | 5  |
|   | 2.2  | Navigation            | 6  |
|   |      | 2.2.1 Experiment view | 6  |
|   |      | 2.2.2 Protein view    | 12 |
|   |      | 2.2.3 Peptide view    | 15 |
| 3 | Tasl | submission            | 16 |
|   | 3.1  | Submission            | 16 |
|   | 3.2  | Selection of results  | 18 |

## 1 Introduction

**decryptor** is a computational system used for detection of variant peptides in *standard* shotgun proteomics data. **decryptor** can be used without sequencing data, as opposed to the more prevalent proteogenomics approach. The detection of variant peptides is thus not guided. In this respect, it enables universal applicability for most shotgun proteomics data. On the other hand, the data are required to be measured with great depth. This is because rare peptides are more common in deeper measurements. In particular, it is expected to detect more than double variant peptides if double of spectra was measured.

## 1.1 Applications

Unaided detection of variant peptides has variety of potential applications. For instance, variant peptides resulting from somatic variant can be used as tumour-specific biomarkers for monitoring of progression of disease. Germline variants can be used for establishment of origin of sample.

## 1.2 Word of caution

The detection of variant peptides is a complicated problem and **decryptor** might give false positives. The most reliably detected variant peptides are polymorphic peptides of population frequency higher than 1%. Therefore extra care should be taken in evaluation of identified somatic variants.

## 2 Browsing results

This section introduces navigation, applicable to already available results. Herein, it is exemplified over guest account, such that each step can be performed without registration. For actual submission of results see the next section.

## 2.1 Login

### 2.1.1 Root page

decryptor's main page informs about its use, i.e., identification of variant peptides, their genomic origin and report of metadata associated with identified variants. Note that there is no need for registration to explore this functionality. We'll continue by using "log-in" link.



decryptor (1.1) analyses data from tandem mass spectrometry of human proteome for presence of point alterations. Subsequently, decryptor deduces DNA/mRNA alterations whenever possible.

> See example. (email: guest, password: guest).

To use decryptor, you need to log-in. If not registered yet, sign-up.

Materials | Release notes | Changelog | Acknowledgement | Contact us



2

### 2.1.2 Login page

We'll login by providing guest account credentials.

| 0             | Please log in to access this page. |
|---------------|------------------------------------|
| Login         |                                    |
|               |                                    |
| Email Address |                                    |
| guest         |                                    |
| Password      |                                    |
| ••••          |                                    |
|               | Login                              |
|               |                                    |

### Menu

- Login
- Register
- Forgot passwordConfirm account

### 2.2 Navigation

### 2.2.1 Experiment view

**Overall results and their filtering** The login lands on experiment view, which corresponds to overall view over evaluated sample (in this case, example). In the following figure, the "Filter results" was expanded. The filters give users additional control over selection of results but can be also used in predefined way (Default/Strict). The standard "Default" filter is one which should preserve most of the true result there, however lacking specificity. The "Strict filter", on the other hand, should give results which are confident. To see explanation of particular fields, hover mouse over the "(?)" symbol, or continue reading following paragraphs.

**X!Tandem E-Value** The filter refers to minimal statistical significance of spectral match (XTandem's HyperScore) to report spectral match. Note however, that the *value does not directly relate to probability that interpretation is correct*. However, as a guideline, at significance level of 0.1, one would expect around 90% of correct results on variant peptides of population frequency higher than 1%. Note however, that this does not extend intuitively for variant peptides of lower population frequency or somatic variants.

**PepNovo+ Tag Support Count** For identification, **decryptor** is tries to read the peptide sequence directly from the spectrum. The sequencing is performed in form of short subsequences, so-called peptide tags (here, set of length of three). These tags are evaluated for correspondence with the peptide sequencing as matched using database search in X!Tandem.

**PTM-Free neighborhood** The value corresponds to the number of amino acid residues neighboring the variant amino acid

to contain no post-translational modifications of mass corresponding to mass of substitution. Thus for instance, if there is a candidate modification of  $N \rightarrow D$ , but there exist *Deamidation* of N, such variant is not reported. Similarly, often  $A \rightarrow S$  happens, but its mass is similar to that of *Oxidation*. Therefore, if M is nearby, it is more likely the *Oxidation* of M than the variant peptide.

**Least peptide count** Minimal number of peptides per protein, for the protein to be reported. Due proteolysis, all peptides from protein are in the sample, or none; therefore it is unlikely that some peptide will be identified without corresponding reference peptides. Therefore, one would expect at least one other reference peptide for variant peptide identified.

## Experiment view

Experiment: SILAC\_R1-13\_TR-C\_

ID: 85bce16568e395e6\_0000

#### Filter results

| Filtering presets:                            | Strict | Default | No filter |
|---|--------|---------|-----------|
| (?) Miminal XITandem -Log10 E-Value:          | 1.0    |         |           |
| (7) Minimal PepNovo+ Tag Support Count:       | 1      |         |           |
| (?) Candidate PTMs alternative explanation:   |        |         |           |
| (?) PTM-Free neighborhood:                    | 0      |         |           |
| (?) Least distinct peptide count for protein: | 2      |         |           |
| Filter results                                |        |         |           |
| Experimental meta-information                 |        |         |           |
| Export results                                |        |         |           |

#### Identification

Summary: 988 proteins, 4539 ref. peptides, 18 non-ref. peptides, 16371 spectra

**Experimental meta-information** The experiment also contains meta-information which was filled in during the submission of the task to help organize the searches. See the next section.

#### Filter results...

#### Experimental meta-information

| Parameter              | Value                 |
|------------------------|-----------------------|
| Fragmentation          | CID                   |
| Protease               | trypsin               |
| Fragment tolerance     | 0.5 Da                |
| Variable modifications | Oxidation (M)         |
| Experiment info        | SILAC_R1-13_TR-C_     |
| ql                     | 127.0.0.1             |
| Mail                   | hruska.miro@gmail.com |
| Fixed modifications    | Carbamidomethyl (C)   |
| Precursor tolerance    | 10 ppm                |
|                        |                       |

Export results

**Proteins with alterations** The most important view consists of proteins with claimed detected peptides. The view contains information about protein, the number of spectra (quantitative information) and peptides (number of distinct peptides per protein) identified. The detrimental effect over protein is aggregated value of predicted detrimental effect of individual variants (as calculated using dbNSFP, v 2.5). Disease relevance column contains information whether particular protein was linked to disease or in cancer (e.g., being an oncogene).

| ¢<br>Protein  | Spectra /<br>Peptides /<br>Unique<br>peptides | ¢<br>Alterations     | Detrimental<br>effect | DNA/mRNA<br>alteration<br>source                         | ¢<br>Disease relevance |
|---|---|----------------------|-----------------------|--|------------------------|
| lactate dehydrogenase B<br>(LDHB)                                 | 106/13/13                                     | 251: A>S<br>252: I>L | 1.39                  |  |                        |
| malate dehydrogenase 2,<br>NAD (mitochondrial) (MDH2)             | 51/11/11                                      | 235: V>I             | 0.67                  | COSMIC v.68<br>—<br>endometrium<br>ICGC 15.1—<br>UCEC-US |                        |
| RNA terminal phosphate<br>cyclase-like 1 (RCL1)                   | 4/3/3   | 106: V>I             | 0.62                  | COSMIC v.68<br>—<br>large_intestine                      |                        |
| eukaryotic translation<br>elongation factor 1 alpha 1<br>(EEF1A1) | 6/4/4   | 231: L>V             | 0.60                  | COSMIC v.68<br>—liver<br>ICGC 15.1—<br>LINC-JP           |                        |
| phosphoglycerate kinase 1<br>(unknown)                            | 10/7/7  | 86: S>T              | 0.54                  | COSMIC v.68<br>—kidney                                   |                        |
| family with sequence<br>similarity 192, member A<br>(FAM192A)     | 5/3/3   | 47: V>I              | 0.49                  | ICGC 15.1—<br>SKCM-US                                    |                        |

#### Proteins with sequence alterations

**Reference proteins** The rest of the view contains information about identified reference proteins.

### Reference proteins

| Protein   | Spectra /<br>Peptides /<br>Unique<br>peptides |            |
|---|---|------------|
| voltage-dependent anion channel 1 (VDAC1)   | 52/10/10                                      |            |
| isocitrate dehydrogenase 3 (NAD+) alpha (unknown)   | 39/10/10                                      |            |
| coproporphyrinogen oxidase (CPOX)   | 33 / 14 / 14                                  | t<br>a the |
| pyrophosphatase (inorganic) 1 (PPA1)  | 29/9/9 O Gra                                  |            |
| methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate<br>cyclohydrolase (unknown) | 28/9/9 O Sele                                 |            |
| guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 (GNB2L1)                                | 27/11/11<br>Effects                           |            |
| ribosomal protein L5 (RPL5)   | 27 / 11 / 11 Include poi                      |            |
| NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa (unknown)  | 26 / 15 / 15 Include the                      |            |
| enolase 1, (alpha) (ENO1)   | 26 / 10 / 10                                  | Nor        |
| UDP-galactose-4-epimerase (GALE)  | 23/9/9  |            |
| pyrroline-5-carboxylate reductase family, member 2 (PYCR2)  | 23/7/7  |            |
| transaldolase 1 (TALDO1)  | 22/10/10                                      |            |

#### 2.2.2 Protein view

**Overall view** The protein view contains information relevant to particular protein and corresponding gene, external links and extracted information from several sources (UniProt, NCBI GeneRif, Gene Ontology).

### Protein view

<< Experiment view

I. Protein/Gene information Protein: eukaryotic translation elongation factor 1 alpha 1 Protein ID: ENSP00000330054 Coverage: 15.15 %, isoform-specific peptides: 1 Synonyms: CCS-3, CCS3, EE1A1, EEF-1, EEF1A, EF-Tu, EF1A, GRAF-1EF, HNGC:16303, LENG7, PTI1, eEF1A-1 External: MIM:130590, HGNC:HGNC:3189, Ensembl:ENSG00000156508, HPRD:00559, Entrez:1915 UniProt summary NCBI GeneRif Gene Ontology II. Protein identification Sequence coverage

Peptides with sequence alteration

Peptide / Spectral count

modifications

Detrimental Affected effect Domains

Alternative mass interpretation

**Sequence coverage** The sequence coverage shows the peptide and its identified subsequences, together with identified alterations.

#### 

#### Gene Ontology

#### II. Protein identification

#### Sequence coverage

| М |             | К      |             | К | Т           | Н      | I           | Ν           | I             | V           | ۷           | I           |             |             | V           |             |             |             | К           |             | Т           | Т           | Т           |             | Н           |             | I           | Y           | К      |             |             |             | I           |             | K | R           | Т           | I           | Е           |
|---|-------------|--------|-------------|---|-------------|--------|-------------|-------------|---------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|--------|-------------|-------------|-------------|-------------|-------------|---|-------------|-------------|-------------|-------------|
| К |             |        | K           | Е | А           | А      | Е           | М           |               | K           |             |             | F           | K           | Y           | A           | W           | V           |             |             | K           |             | К           | А           |             | R           | Е           | R           |        | Ι           | Т           | I           |             | I           |   |             | W           | К           | F           |
| Е | Т           |        | K           | Y | Y           | ۷      | т           | I           | I             | D           | Α           | Ρ           | G           | Н           | R           |             | F           | I           | К           | Ν           | М           | I           | Т           |             | Т           |             |             | А           |        |             | A           | V           |             | I           | V | А           | А           |             | V           |
|   |             |        |             | A |             |        |             | K           | Ν             |             |             |             |             |             |             | A           |             |             | Α           | Y           | Т           |             |             | V           | K           |             |             | I           | V      |             | V           | Ν           | K           | М           |   |             | Т           | Е           | Ρ           |
| Ρ | Y           |        | Q           | K | R           | Y      | Е           | Е           | I             | ۷           | Κ           |             | V           |             | Т           | Y           | I           | K           | К           | I           |             | Y           | Ν           |             |             | Т           | ۷           | А           | F      | V           |             | I           |             |             | W | Ν           |             |             | Ν           |
| М |             |        |             |   | А           | Ν      | М           |             | W             |             | K           |             | W           | K           | V           | Т           | R           | K           | D           | G           | Ν           | Α           | S           | G           | т           | Т           | L           | L           | E      | А           | τ           | D           | С           | I           | L | Ρ           | Ρ           | Т           | R           |
| - |             |        |             |   |             |        |             |             |               |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |        |             |             |             |             |             |   |             |             |             | _           |
| Ρ | т           | D      | K           | Ρ | L           | R      |             |             |               |             |             | V           |             | K           |             |             |             |             |             |             | V           |             |             |             |             | V           | E           | Т           | G      | v           | L           | κ           | Ρ           | G           | M | V           | V           | т           | F           |
|   |             |        |             |   |             | R<br>T |             |             |               |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |        |             | _           |             |             | _           |   |             |             | D           |             |
| A | Ρ           | ۷      | N           | ۷ | Т           | T      | E           | v           |               |             | V           |             | Μ           |             | Н           | E           | A           |             |             |             | A           |             | Ρ           |             |             | N           | V           |             |        | N           | v           | K           | N           | V           |   | V           | K           |             | V           |
| R | P<br>R      | V<br>G | N           | V | T           | T<br>G | E<br>D      | V<br>S      | K<br>K        | S           | V<br>D      | E<br>P      | M<br>P      | H           | H<br>E      | E<br>A      | A           |             |             | E<br>T      | A<br>A      | L<br>Q      | P<br>V      | G           | D<br>I      | N           | V<br>N      | G           | F<br>P | NG          | v<br>Q      | K           | N           | V           |   | V<br>Y      | K           |             | V           |
| R | P<br>R<br>D | G<br>G | N<br>N<br>H | V | T<br>A<br>A | T<br>G | E<br>D<br>I | V<br>S<br>A | <b>К</b><br>К | S<br>N<br>K | V<br>D<br>F | E<br>P<br>A | M<br>P<br>E | H<br>M<br>L | H<br>E<br>K | E<br>A<br>E | A<br>A<br>K | L<br>G<br>I | S<br>F<br>D | E<br>T<br>R | A<br>A<br>R | L<br>Q<br>S | P<br>V<br>G | G<br>I<br>K | D<br>I<br>K | N<br>L<br>L | V<br>N<br>E | G<br>H<br>D | F<br>P | N<br>G<br>P | V<br>Q<br>K | K<br>I<br>F | N<br>S<br>L | V<br>A<br>K |   | V<br>Y<br>G | K<br>A<br>D | D<br>P<br>A | V<br>V<br>A |

#### Peptides with sequence alteration

| Peptide / Spectral count               | modifications        | Detrimental<br>effect | Affected<br>Domains                 | Alternative mass<br>interpretation |
|--|----------------------|-----------------------|-------------------------------------|------------------------------------|
| DGNASGTTLLEA[L>V]DCILPPTRPTDKPLR<br>/1 | [14]:Carbamidomethyl | 60.0 %                | IPR004539<br>IPR027417<br>IPR000795 |                                    |

**D** (1911)

**Detrimental effect** Clicking the number of detrimental effect at particular peptide expands the aggregated value into its consituent parts as predicted by dbNSFP.

#### NORI Generii

#### Gene Ontology

\_

II. Protein identificat<sup>®</sup> Details

|   | Dotalo                     |                |                                       |        |
|---|----------------------------|----------------|---------------------------------------|--------|
| Sequence coverag                                  | Predictor                  | Effect         | Predictor                             | Effect |
| MGKEKTHINI V<br>KFEKEAAEMG K                      | GERP++ RS                  | 22.7%          | phyloP46way primate                   | 68.6%  |
| ETSK <b>YYVTII D</b><br>GEFEAGISKN G              | phyloP100way vertebrate    | 25.0%          | MutationTaster converted              | 70.8%  |
| PYSQKR <b>YEEI V</b><br>MLEPSANMPW F              | SiPhy 29way logOdds        | 30.5%          | FATHMM                                | 71.1%  |
| PTDKPLRLPL Q                                      | phyloP46way placental      | 30.8%          | LR                                    | 73.7%  |
| APVNVTTEVK S<br>RRGNVAGDSK N                      | phastCons100way vertebrate | 39.6%          | RadialSVM                             | 75.5%  |
| LDCHTAHIAC K<br>IVDMVPGKPM C                      | CADD raw                   | 52.4%          | MutationAssessor                      | 77.1%  |
| VDKKAAGAGK V                                      | Polyphen2 HDIV             | 59.0%          | phastCons46way placental              | 80.4%  |
| Peptides with sequ                                | VEST3                      | 63.4%          | phastCons46way primate                | 81.0%  |
|   | LRT converted              | 64.4%          | SIFT converted                        | 87.9%  |
| Peptide / Spectral count                          |                            |                |                                       |        |
| DGNASGTTLLEA <mark>(L&gt;V)</mark> DCILPPTR<br>/1 | PTDKPLR [14]:Carbamidometh | yl <u>60.0</u> | % IPR004539<br>IPR027417<br>IPR000795 |        |

**Alteration details** For more detailed information, the alteration detail contains the source of this alteration, where it was observed and source-specific details.

| 228497, 74228496: CTG > |
|-------------------------|
|                         |
|                         |
| LINC-JP                 |
| Liver Cancer - NCC, JP  |
| MU864280                |
| G                       |
| G                       |
| С                       |
| not tested              |
| primary tumour          |
| HOC                     |
| None                    |
|                         |

### 2.2.3 Peptide view

One could also see the details of identification of particular peptide from spectral match. This view contains additional mass-spectrometric data such as charge, *mz* and retention time. The E-Value column contains log10 of statistical significance of spectral match (X!Tandem, HyperScore). Further one could see alternative explanations of observed mass changes with respect to reference peptide. In this case, there are no other explanations known. The modifications are drawn from UniMod.

### Peptide view

<< Protein view

#### Peptide sequence: DGNASGTTLLEAVDCILPPTRPTDKPLR

Peptide-spectrum matches

| sequence                     | modifications            | charge | MZ          | RT        | XTandem -<br>Log <sub>10</sub> E-Value | Alteration              | Alternative<br>intepretation of<br>alteration |
|------------------------------|--------------------------|--------|-------------|-----------|--|-------------------------|---|
| DGNASGTTLLEAVDCILPPTRPTDKPLR | 15:<br>(Carbamidomethyl) | 3      | 1003.189819 | 4730.4682 | 2.823909                               | L>V<br>(-14.0156<br>Da) |   |

### 3 Task submission

For the ability to submit tasks, user needs to be registered by filling up the corresponding registration form.

### 3.1 Submission

During the submission, the usual mass-spectrometric information is filled in; moreover, last configuration of modifications can be reloaded. The user is informed on completion of the evaluation, if e-mail is provided. Please note that although decryptor supports wide variety of modifications (obtained from UniMod), its use with data with unusual modifications was not tested and its performance is not guaranteed.

| MS/MS files [.mzt/L, .mzX/L, .mz | gf; Spectra | ptor<br>a convertor) (max: 4 GB)  |   |
|----------------------------------|-------------|---|---|
| Choose Files No file chosen      |             |   |   |
| (7) Fixed modifications          |             | (?) Filter modifications  |   |
|                                  | * <<        | (7) Modifications   |   |
| (7) Variable modifications       |             | 15dB-biotin (C +626.39 Da)<br>2-succinyl (C +117.02 Da)<br>2HPG (R +282.05 Da)<br>3-deoxyglucosone (R +144.04 II<br>3-ulifo (N-term +183.98 Da)<br>4-ONE (C +154.10 Da)<br>4-ONE (C +154.10 Da) | • |
| (?) Protease                     |             |   |   |
| trypsin                          |             |   | • |
| (7) Fragmentation                |             |   |   |
| CD                               |             |   | • |
| (7) Precursor tolerance          |             |   |   |
| 10 ppm                           |             |   |   |
| (7) Fragment tolerance           |             |   |   |
| 0.5 Da                           |             |   |   |
| (7) Mail                         |             |   |   |
| hruska.miro@gmail.com            |             |   |   |

decrypt

## 3.2 Selection of results

The results can be then accessed through the experiment list.

#### ecryptor submit tasks experiment list

user (hruska.miro@gmail.cor

### Experiment list view

| id                    | info              | status | time                |
|-----------------------|-------------------|--------|---------------------|
| 65586297004beb43_0000 | 109_03            | view   | 2016-11-01 20:08:01 |
| 1410f4c5c8f33b91_0000 | 10_01             | view   | 2016-11-01 15:59:16 |
| 281867cc686b8072_0000 | spe-X             | view   | 2016-11-01 15:56:52 |
| ede85d14f0c35939_0000 | SILAC_R2-20_TR-C_ | view   | 2015-11-15 16:11:42 |
| bdf38825a6f7cfde_0000 | act               | view   | 2015-11-15 16:08:05 |
| 9cd623b520780c97_0000 | SILAC_R2-05_TR-B_ | view   | 2015-09-11 09:32:40 |
| 6d357e3d96d86bcc_0000 | Peptide_011       | view   | 2015-09-11 09:29:05 |
| 3e0947b0df7ec122_0000 | act               | view   | 2015-09-11 08:53:44 |
| 871422d35bd4e066_0000 | act               | view   | 2015-09-11 08:49:55 |
| 69aa7cc5c10ed076_0000 | act_00000_00020   | view   | 2015-09-11 08:26:14 |
| 91b5a6f362795ba6_0001 | act2              | view   | 2015-04-15 14:05:13 |
| 91b5a6f362795ba6_0000 | act               | view   | 2015-04-15 14:05:13 |